EW Edwards Lifesciences Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:11
Jul 28
Jul 28
UBS, Leerink Partners, BofA, JPMorgan, Truist, Exane BNP Paribas.
UBS, Leerink Partners, BofA, JPMorgan, Truist, Exane BNP Paribas, and Wells Fargo issued multiple analyst upgrades and initiations across a range of stocks including Edwards Lifesciences, Enovis, Gossamer Bio, Honeywell, International Paper, Intuitive Surgical, Magnolia Oil & Gas, Nutrien, QXO, and Stryker.
07:18
Jul 25
Jul 25
Edwards Lifesciences has held its value, beaten earnings estimates, and sees continued growth in minimally invasive heart valves; June sales and earnings also beat. Expanded Medicare coverage and an upcoming clinical trial readout provide catalysts; the stock is still at $84 with analyst target of $100 (19% upside). Edwards is a clean growth story in large-cap medtech at a reasonable valuation, offering relative safety within the sector. Clinical trial miss; Medicare policy changes; competition from newer valve technologies.
HIGH
12:47
Jul 24
Jul 24
US pre-market movers show Intel up on strong earnings and guidance.
US pre-market movers show Intel up on strong earnings and guidance, American Express down on revenue and profit guidance miss, Oracle up on a Navy contract, and Charter Communications down on broadband subscriber losses.
12:47
Jul 24
Jul 24
US pre-market movers show Intel up on strong earnings and guidance.
US pre-market movers show Intel up on strong earnings and guidance, American Express down on revenue and profit miss, Oracle up on Navy contract, and Charter down on broadband subscriber decline.
02:39
Jul 24
Jul 24
JPMorgan raised its price target on Edwards Lifesciences Corp.
JPMorgan raised its price target on Edwards Lifesciences Corp. to $105, up from the previous target of $100.
17:00
Jul 23
Jul 23
Management raised full-year guidance across all segments, citing durable competitive advantages in TAVR and accelerating TMTT portfolio adoption, signaling confidence in sustained mid-to-high single-digit TAVR growth and 10% total company growth long-term.
HIGH
12:00
Jun 16
Jun 16
SpaceX rises 7.3% in premarket, Mag 7 stocks are mixed, Domo drops 13% on strategic review.
SpaceX rises 7.3% in premarket, Mag 7 stocks are mixed, Domo drops 13% on strategic review, Edgewise falls 23% on trial results, Edwards Lifesciences gains 3.1% on coverage proposal, Huntsman drops 7% on merger with Olin, and Robinhood gains 2% on workforce reduction.
11:45
Jun 03
Jun 03
The impact of the US low-risk TAVR data is reflected in a flattening of US revenue for this segment, but the company indicates stabilization over last 8 weeks, which could be a short-term bottoming in this market. — Signals a potential bottom in Medtronic's US TAVR market share and could relieve pressure on Edwards Lifesciences if the stabilization holds.
MED
14:00
Apr 23
Apr 23
Management raised full-year guidance across total company, TAVR, and EPS, citing strong Q1 momentum and broad-based growth, signaling improving confidence in the durable multi-year growth trajectory.
HIGH
17:00
Feb 10
Feb 10
Management expressed heightened confidence in 2026 guidance (8-10% sales growth, $2.90-$3.05 EPS) citing strong Q4 momentum, multiple growth catalysts, and durable evidence-driven tailwinds.
HIGH
21:30
Feb 04
Feb 04
The 50 new programs added across 43 unique brands in the biopharma services segment, and the digitization of enrollment for more than 1,600 specialty drugs, points to a structural volume ramp in the prior authorization space. — This positions McKesson's PTS segment as the 'plumbing' for prior authorizations, having scale advantages that are hard to replicate, and is a volume story independent of specific drug class (e.g., oral GLP-1s).
MED
17:00
Oct 30
Oct 30
Management raised full-year guidance on the back of stronger-than-expected Q3, citing renewed clinical focus on TAVR and positive data; tone is confident about sustainable multi-year growth.
HIGH
About EW Analyst Coverage
Buzzberg tracks EW (Edwards Lifesciences) across 6 sources. 1 bullish vs 0 bearish calls from 9 analysts. Sentiment: predominantly bullish (8%). 12 total trade ideas tracked. Latest voices: DeItaone, u/raytoei, Newsquawk.